Arch Therapeutics

153 articles about Arch Therapeutics

• Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

  4/13/2022

  Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical devices, announced that two clinical case reports on the use of AC5® Advanced Wound System were presented as Poster Presentations and three additional cases were presented during a live Open Air Studio session at the 2022 Symposium on Advanced Wound Care Spring.

• Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

  4/4/2022

  Arch Therapeutics, Inc. today announced that two clinical case report abstracts of AC5 ®  Advanced Wound System were accepted for Poster Presentations at the upcoming 2022 Symposium on Advanced Wound Care (SAWC) Spring.

• Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System

  3/14/2022

  Arch Therapeutics, Inc. today announced it has entered into a distribution agreement with Centurion Therapeutics Inc. to expand sales opportunities for AC5 ® Advanced Wound System.

• Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds

  1/6/2022

  Arch Therapeutics, Inc. today announced a study of its proprietary adaptive self-assembling barrier scaffold (aSABS) and peptide technology, AC5 ® Advanced Wound System.

• Arch Therapeutics Announces Appointment of Guy Fish to the BoardBrings Broad Industry Experience in Strategy and Execution

  1/4/2022

  Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical devices, announced the appointment of Guy Fish, M.D. to its Board of Directors.

• Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System

  12/13/2021

  Arch Therapeutics, Inc. today announced that in partnership with Lovell Government Services, Arch’s AC5 ® Advanced Wound System (“AC5 ® ”) has been added to the Federal Supply Schedule (“FSS”) and General Services Administration (“GSA”) contracts.

• Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program

  12/1/2021

  Arch Therapeutics, Inc. announced today that it has added a key opinion leader (KOL) interview to its Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care.

• Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC)

  11/1/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical devices, presented at the Symposium on Advanced Wound Care (SAWC) during the “Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care” session on October 31, 2021.

• Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) FallAC5® Advanced Wound System Selected for Innovation Spotlight

  10/25/2021

  Arch Therapeutics, Inc. today announced that it will be presenting at the 2021 Symposium on Advanced Wound Care (SAWC) Fall.

• Arch Therapeutics Provides Corporate Update

  10/13/2021

  Arch Therapeutics, Inc. today provided a corporate update at the LD Micro Main Event XIV investor conference in Los Angeles, CA.

• Arch Therapeutics to Present at the LD Micro Main EventIn-Person Presentation on October 13, 2021

  10/6/2021

  Arch Therapeutics, Inc. will be featured as a presenting company at the LD Micro Main Event XIV. The conference is being held October 12th - 14th, 2021 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA.

• Arch Therapeutics Launches Coverage and Reimbursement PilotCritical Next Step in Commercialization Plan Commences

  10/4/2021

  Arch Therapeutics, Inc. today announced the launch of its coverage and reimbursement pilot (the “Pilot”) in collaboration with The Reimbursement Group (“TRG”) for the Company’s AC5 ® Advanced Wound System.

• Arch Therapeutics Announces Appointment of Larry Hicks to the BoardBrings deep industry experience to support commercialization plan

  9/30/2021

  Arch Therapeutics, Inc. today announced the appointment of Larry Hicks to its Board of Directors.

• Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales

  7/12/2021

  Arch Therapeutics, Inc. today announced that Dan Yrigoyen has joined the organization as Vice President of Sales.

• Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021

  7/7/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcoming Ladenburg Thalmann 2021 Healthcare Conference, which shall be held July 13-14, 2021.

• Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

  6/2/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021

• Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC)

  5/10/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, presents two clinical case reports supporting the broad potential of AC5 ® Advanced Wound System in chronic and non-healing wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Spring this week.

• Arch Therapeutics Appoints Michael S. Abrams its Chief Financial OfficerCompany Prepares for Next Stage of Growth

  5/3/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021.

• Arch Therapeutics to Present AC5® Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC)Additional case studies support the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds

  4/27/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case report abstracts of AC5 ® Advanced Wound System will be presented at the upcoming 2021 Symposium on Advanced Wound Care (SAWC).

• Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results2021: Executing on Opportunities and Preparing for the Future

  4/19/2021

  Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in line with its commitment to maintain continuing dialogue with investors and other stakeholders on the progress and development of the Company. Commercializing AC5 ® Advanced Wound System As Arch transitions to a commercialization stage